Symbols / ZNTL Stock $3.89 +1.30% Zentalis Pharmaceuticals, Inc.
ZNTL (Stock) Chart
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 275.92M | Enterprise Value | 66.06M | Income | -137.06M | Sales | — | Book/sh | 3.13 | Cash/sh | 3.47 |
| Dividend Yield | — | Payout | 0.00% | Employees | 106 | IPO | — | P/E | — | Forward P/E | -2.50 |
| PEG | — | P/S | — | P/B | 1.24 | P/C | — | EV/EBITDA | -0.47 | EV/Sales | — |
| Quick Ratio | 6.73 | Current Ratio | 6.93 | Debt/Eq | 18.30 | LT Debt/Eq | — | EPS (ttm) | -1.91 | EPS next Y | -1.55 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-14 | ROA | -24.48% | ROE | -49.54% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 70.93M | Shs Float | 48.67M | Short Float | 7.53% |
| Short Ratio | 6.76 | Short Interest | — | 52W High | 6.95 | 52W Low | 1.13 | Beta | 1.66 | Avg Volume | 1.88M |
| Volume | 1.43M | Target Price | $6.25 | Recom | Buy | Prev Close | $3.84 | Price | $3.89 | Change | 1.30% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-10 | main | Guggenheim | Buy → Buy | $10 |
| 2026-03-27 | reit | Guggenheim | Buy → Buy | $6 |
| 2025-11-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $4 |
| 2025-08-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $5 |
| 2025-05-15 | reit | Wedbush | Neutral → Neutral | $4 |
| 2025-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | Wedbush | Neutral → Neutral | $4 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-01-30 | main | Wells Fargo | Equal-Weight → Equal-Weight | $6 |
| 2025-01-29 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-01-28 | main | UBS | Neutral → Neutral | $2 |
| 2024-11-15 | main | Guggenheim | Buy → Buy | $8 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-09-16 | reit | Oppenheimer | Outperform → Outperform | $20 |
| 2024-08-12 | up | Wedbush | Underperform → Neutral | $4 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-20 | down | UBS | Buy → Neutral | $5 |
| 2024-06-18 | down | Wells Fargo | Overweight → Equal-Weight | $9 |
| 2024-06-18 | main | Stifel | Buy → Buy | $10 |
- Ovarian cancer drug combo data lands June ASCO presentation - Stock Titan ue, 21 Apr 2026 14
- $ZNTL stock is down 9% today. Here's what we see in our data. - Quiver Quantitative hu, 16 Apr 2026 19
- ZNTL: Zentalis Presents Promising Data on Azenosertib at AACR 20 - GuruFocus Sat, 18 Apr 2026 03
- Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance hu, 08 Jan 2026 08
- What's Behind The Surge In Zentalis Stock? - Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Benzinga Fri, 10 Apr 2026 07
- Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com hu, 08 Jan 2026 08
- Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st Wed, 07 Jan 2026 08
- Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha ue, 18 Nov 2025 08
- Is Zentalis Pharmaceuticals (ZNTL) Stock Gaining Momentum | Price at $2.66, Up 1.14% - Expert Market Insights - Cổng thông tin điện tử tỉnh Tây Ninh Mon, 06 Apr 2026 07
- Ovarian cancer drug moves toward pivotal trials with 400mg dose - Stock Titan hu, 09 Apr 2026 07
- ZNTL Stock Update: Morgan Stanley Lowers Price Target by 50% | Z - GuruFocus Wed, 12 Nov 2025 08
- $ZNTL stock is up 28% today. Here's what we see in our data. - Quiver Quantitative ue, 06 Jan 2026 08
- Two new Zentalis hires get stock options priced at $2.57 - Stock Titan Wed, 01 Apr 2026 07
- Jefferies raises Zentalis stock price target on ovarian cancer trial data - Investing.com Fri, 10 Apr 2026 07
- Insider Purchase: 10% owner at $ZNTL Buys 6,459,973 Shares - Quiver Quantitative hu, 08 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
-100.00%
|
67.42
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
-100.00%
|
67.42
|
0.00
|
0.00
|
| Operating Expense |
|
145.01
-43.11%
|
254.88
+0.37%
|
253.94
+11.73%
|
227.29
|
| Research And Development |
|
107.30
-36.05%
|
167.77
-11.51%
|
189.59
+9.76%
|
172.73
|
| Selling General And Administration |
|
37.72
-56.70%
|
87.11
+35.37%
|
64.35
+17.96%
|
54.55
|
| General And Administrative Expense |
|
37.72
-56.70%
|
87.11
+35.37%
|
64.35
+17.96%
|
54.55
|
| Other Gand A |
|
37.72
-56.70%
|
87.11
+35.37%
|
64.35
+17.96%
|
54.55
|
| Total Expenses |
|
145.01
-43.11%
|
254.88
+0.37%
|
253.94
+11.73%
|
227.29
|
| Operating Income |
|
-145.01
+22.64%
|
-187.46
+26.18%
|
-253.94
-11.73%
|
-227.29
|
| Total Operating Income As Reported |
|
-152.81
+20.08%
|
-191.19
+36.16%
|
-299.51
-31.78%
|
-227.29
|
| EBITDA |
|
-144.27
+22.50%
|
-186.17
+26.28%
|
-252.55
-11.82%
|
-225.86
|
| Normalized EBITDA |
|
-152.67
+26.58%
|
-207.94
+9.44%
|
-229.60
+0.97%
|
-231.85
|
| Reconciled Depreciation |
|
0.74
-42.67%
|
1.29
-7.20%
|
1.39
-2.59%
|
1.43
|
| EBIT |
|
-145.01
+22.64%
|
-187.46
+26.18%
|
-253.94
-11.73%
|
-227.29
|
| Total Unusual Items |
|
8.39
-61.44%
|
21.77
+194.85%
|
-22.95
-483.35%
|
5.99
|
| Total Unusual Items Excluding Goodwill |
|
8.39
-61.44%
|
21.77
+194.85%
|
-22.95
-483.35%
|
5.99
|
| Special Income Charges |
|
-7.80
-108.67%
|
-3.74
+91.80%
|
-45.57
|
0.00
|
| Other Special Charges |
|
—
|
—
|
45.57
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
3.74
|
0.00
|
0.00
|
| Restructuring And Mergern Acquisition |
|
7.80
|
0.00
|
0.00
|
—
|
| Net Income |
|
-137.06
+17.35%
|
-165.84
+43.24%
|
-292.19
-23.39%
|
-236.81
|
| Pretax Income |
|
-136.62
+17.55%
|
-165.69
+40.16%
|
-276.89
-25.12%
|
-221.30
|
| Other Income Expense |
|
8.39
-61.44%
|
21.77
+194.85%
|
-22.95
-483.35%
|
5.99
|
| Gain On Sale Of Security |
|
16.19
-36.52%
|
25.50
+12.76%
|
22.62
+277.77%
|
5.99
|
| Gain On Sale Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Tax Provision |
|
0.44
+149.72%
|
0.18
+129.45%
|
-0.60
-28.14%
|
-0.47
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+10400.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
1.76
-61.44%
|
4.57
+10058.78%
|
-0.05
-483.35%
|
0.01
|
| Net Income Including Noncontrolling Interests |
|
-137.06
+17.37%
|
-165.87
+43.26%
|
-292.31
-23.28%
|
-237.11
|
| Net Income From Continuing Operation Net Minority Interest |
|
-137.06
+17.35%
|
-165.84
+43.24%
|
-292.19
-23.39%
|
-236.81
|
| Net Income From Continuing And Discontinued Operation |
|
-137.06
+17.35%
|
-165.84
+43.24%
|
-292.19
-23.39%
|
-236.81
|
| Net Income Continuous Operations |
|
-137.06
+17.37%
|
-165.87
+43.26%
|
-292.31
-23.28%
|
-237.11
|
| Minority Interests |
|
0.00
-100.00%
|
0.03
-75.44%
|
0.11
-62.87%
|
0.31
|
| Normalized Income |
|
-143.69
+21.50%
|
-183.04
+32.03%
|
-269.29
-10.92%
|
-242.78
|
| Net Income Common Stockholders |
|
-137.06
+17.35%
|
-165.84
+43.24%
|
-292.19
-23.39%
|
-236.81
|
| Diluted EPS |
|
—
|
-2.33
+47.87%
|
-4.47
+0.22%
|
-4.48
|
| Basic EPS |
|
—
|
-2.33
+47.87%
|
-4.47
+0.22%
|
-4.48
|
| Basic Average Shares |
|
—
|
71.08
+8.67%
|
65.41
+23.75%
|
52.86
|
| Diluted Average Shares |
|
—
|
71.08
+8.67%
|
65.41
+23.75%
|
52.86
|
| Diluted NI Availto Com Stockholders |
|
-137.06
+17.35%
|
-165.84
+43.24%
|
-292.19
-23.39%
|
-236.81
|
| Earnings From Equity Interest Net Of Tax |
|
0.00
|
0.00
+100.00%
|
-16.01
+1.65%
|
-16.28
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
288.97
-32.85%
|
430.34
-22.00%
|
551.69
+2.30%
|
539.31
|
| Current Assets |
|
253.19
-34.42%
|
386.07
-22.28%
|
496.72
+9.91%
|
451.93
|
| Cash Cash Equivalents And Short Term Investments |
|
245.89
-33.74%
|
371.08
-23.16%
|
482.92
+10.41%
|
437.37
|
| Cash And Cash Equivalents |
|
35.99
+6.18%
|
33.90
+20.91%
|
28.04
-34.90%
|
43.07
|
| Other Short Term Investments |
|
209.90
-37.75%
|
337.18
-25.87%
|
454.88
+15.36%
|
394.30
|
| Receivables |
|
0.00
-100.00%
|
5.00
|
0.00
-100.00%
|
7.04
|
| Accounts Receivable |
|
—
|
—
|
—
|
—
|
| Other Receivables |
|
—
|
5.00
|
—
|
6.53
|
| Accrued Interest Receivable |
|
—
|
—
|
—
|
0.51
|
| Prepaid Assets |
|
—
|
—
|
—
|
14.56
|
| Restricted Cash |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
7.30
-26.89%
|
9.98
-27.66%
|
13.80
-5.24%
|
14.56
|
| Total Non Current Assets |
|
35.78
-19.19%
|
44.27
-19.46%
|
54.97
-37.09%
|
87.38
|
| Net PPE |
|
29.04
-21.99%
|
37.23
-10.80%
|
41.73
-16.66%
|
50.08
|
| Gross PPE |
|
31.82
-23.34%
|
41.50
-7.54%
|
44.88
-13.91%
|
52.14
|
| Accumulated Depreciation |
|
-2.77
+35.10%
|
-4.27
-35.77%
|
-3.15
-52.82%
|
-2.06
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
1.38
-3.30%
|
1.42
-4.50%
|
1.49
-32.73%
|
2.21
|
| Construction In Progress |
|
—
|
0.00
-100.00%
|
0.17
+367.57%
|
0.04
|
| Other Properties |
|
26.27
-26.84%
|
35.91
-7.89%
|
38.98
-13.36%
|
44.99
|
| Leases |
|
4.17
+0.00%
|
4.17
-1.58%
|
4.24
-13.41%
|
4.89
|
| Goodwill And Other Intangible Assets |
|
—
|
0.00
-100.00%
|
3.74
+0.00%
|
3.74
|
| Goodwill |
|
—
|
0.00
-100.00%
|
3.74
+0.00%
|
3.74
|
| Investments And Advances |
|
—
|
—
|
0.00
-100.00%
|
21.21
|
| Long Term Equity Investment |
|
—
|
—
|
0.00
-100.00%
|
21.21
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
9.72
|
| Other Non Current Assets |
|
6.74
-4.39%
|
7.04
-25.84%
|
9.50
-23.09%
|
12.35
|
| Total Liabilities Net Minority Interest |
|
72.76
-21.89%
|
93.15
-18.50%
|
114.30
+8.56%
|
105.29
|
| Current Liabilities |
|
36.56
-30.66%
|
52.73
-23.99%
|
69.37
+22.45%
|
56.65
|
| Payables And Accrued Expenses |
|
36.56
-30.66%
|
52.73
-23.99%
|
69.37
+22.45%
|
56.65
|
| Payables |
|
7.21
-3.09%
|
7.44
-50.17%
|
14.93
+32.71%
|
11.25
|
| Accounts Payable |
|
7.21
-3.09%
|
7.44
-50.17%
|
14.93
+32.71%
|
11.25
|
| Current Accrued Expenses |
|
29.35
-35.19%
|
45.29
-16.81%
|
54.44
+19.91%
|
45.40
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
—
|
—
|
| Total Tax Payable |
|
—
|
—
|
—
|
—
|
| Income Tax Payable |
|
—
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
36.20
-10.44%
|
40.43
-10.02%
|
44.93
-7.63%
|
48.64
|
| Long Term Debt And Capital Lease Obligation |
|
35.70
-9.79%
|
39.58
-8.28%
|
43.15
-4.46%
|
45.17
|
| Long Term Capital Lease Obligation |
|
35.70
-9.79%
|
39.58
-8.28%
|
43.15
-4.46%
|
45.17
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.85
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.85
|
| Other Non Current Liabilities |
|
0.50
-41.11%
|
0.85
-52.30%
|
1.78
-32.06%
|
2.62
|
| Stockholders Equity |
|
216.20
-35.88%
|
337.19
-22.89%
|
437.28
+0.80%
|
433.80
|
| Common Stock Equity |
|
216.20
-35.88%
|
337.19
-22.89%
|
437.28
+0.80%
|
433.80
|
| Capital Stock |
|
0.07
-2.82%
|
0.07
+1.43%
|
0.07
+18.64%
|
0.06
|
| Common Stock |
|
0.07
-2.82%
|
0.07
+1.43%
|
0.07
+18.64%
|
0.06
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
69.09
-3.08%
|
71.28
+0.73%
|
70.77
+19.37%
|
59.28
|
| Ordinary Shares Number |
|
69.09
-3.08%
|
71.28
+0.73%
|
70.77
+19.37%
|
59.28
|
| Additional Paid In Capital |
|
1,407.39
+1.18%
|
1,390.95
+5.09%
|
1,323.58
+28.32%
|
1,031.46
|
| Retained Earnings |
|
-1,191.45
-13.00%
|
-1,054.39
-18.66%
|
-888.56
-49.00%
|
-596.37
|
| Gains Losses Not Affecting Retained Earnings |
|
0.20
-64.87%
|
0.56
-74.57%
|
2.19
+262.16%
|
-1.35
|
| Minority Interest |
|
—
|
0.00
-100.00%
|
0.11
-51.58%
|
0.22
|
| Other Equity Adjustments |
|
0.20
-64.87%
|
0.56
-74.57%
|
2.19
+262.16%
|
-1.35
|
| Total Equity Gross Minority Interest |
|
216.20
-35.88%
|
337.19
-22.91%
|
437.39
+0.78%
|
434.02
|
| Total Capitalization |
|
216.20
-35.88%
|
337.19
-22.89%
|
437.28
+0.80%
|
433.80
|
| Working Capital |
|
216.63
-35.01%
|
333.34
-22.00%
|
427.35
+8.11%
|
395.29
|
| Invested Capital |
|
216.20
-35.88%
|
337.19
-22.89%
|
437.28
+0.80%
|
433.80
|
| Total Debt |
|
35.70
-9.79%
|
39.58
-8.28%
|
43.15
-4.46%
|
45.17
|
| Capital Lease Obligations |
|
35.70
-9.79%
|
39.58
-8.28%
|
43.15
-4.46%
|
45.17
|
| Net Tangible Assets |
|
216.20
-35.88%
|
337.19
-22.23%
|
433.55
+0.81%
|
430.07
|
| Tangible Book Value |
|
216.20
-35.88%
|
337.19
-22.23%
|
433.55
+0.81%
|
430.07
|
| Investmentsin Associatesat Cost |
|
—
|
—
|
0.00
-100.00%
|
21.21
|
| Investmentsin Joint Venturesat Cost |
|
—
|
—
|
—
|
21.21
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-125.25
+26.70%
|
-170.86
+17.79%
|
-207.82
-26.91%
|
-163.75
|
| Cash Flow From Continuing Operating Activities |
|
-125.25
+26.70%
|
-170.86
+17.79%
|
-207.82
-26.91%
|
-163.75
|
| Net Income From Continuing Operations |
|
-137.06
+17.37%
|
-165.87
+43.26%
|
-292.31
-23.28%
|
-237.11
|
| Depreciation Amortization Depletion |
|
0.74
-42.67%
|
1.29
-7.20%
|
1.39
-2.59%
|
1.43
|
| Depreciation And Amortization |
|
0.74
-42.67%
|
1.29
-7.20%
|
1.39
-2.59%
|
1.43
|
| Other Non Cash Items |
|
—
|
-47.42
-415.22%
|
15.04
|
—
|
| Stock Based Compensation |
|
20.72
-69.20%
|
67.27
+22.70%
|
54.82
+17.04%
|
46.84
|
| Asset Impairment Charge |
|
4.14
+10.71%
|
3.74
-24.57%
|
4.95
|
0.00
|
| Deferred Tax |
|
0.00
|
0.00
+100.00%
|
-0.85
-10.92%
|
-0.77
|
| Deferred Income Tax |
|
0.00
|
0.00
+100.00%
|
-0.85
-10.92%
|
-0.77
|
| Operating Gains Losses |
|
-0.66
-617.39%
|
-0.09
-100.56%
|
16.42
+0.50%
|
16.34
|
| Unrealized Gain Loss On Investment Securities |
|
-1.24
+76.30%
|
-5.23
|
0.00
|
0.00
|
| Gain Loss On Sale Of PPE |
|
-0.66
-4976.92%
|
-0.01
-103.20%
|
0.41
+625.00%
|
0.06
|
| Change In Working Capital |
|
-9.12
+44.85%
|
-16.54
-382.06%
|
5.86
-55.75%
|
13.25
|
| Change In Receivables |
|
5.00
+200.00%
|
-5.00
|
0.00
|
0.00
|
| Changes In Account Receivables |
|
5.00
+200.00%
|
-5.00
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
2.99
-51.87%
|
6.22
+209.51%
|
-5.68
+14.03%
|
-6.61
|
| Change In Payables And Accrued Expense |
|
-17.32
+3.92%
|
-18.02
-265.05%
|
10.92
-29.68%
|
15.53
|
| Change In Payable |
|
-17.32
+3.92%
|
-18.02
-265.05%
|
10.92
-29.68%
|
15.53
|
| Change In Account Payable |
|
-17.32
+3.92%
|
-18.02
-265.05%
|
10.92
-29.68%
|
15.53
|
| Change In Other Working Capital |
|
0.20
-23.86%
|
0.26
-57.62%
|
0.62
-85.61%
|
4.33
|
| Investing Cash Flow |
|
131.62
-25.45%
|
176.56
+497.14%
|
-44.46
+61.06%
|
-114.18
|
| Cash Flow From Continuing Investing Activities |
|
131.62
-25.45%
|
176.56
+497.14%
|
-44.46
+61.06%
|
-114.18
|
| Net PPE Purchase And Sale |
|
0.70
+547.44%
|
-0.16
+73.24%
|
-0.58
+77.12%
|
-2.55
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.22
+62.09%
|
-0.58
+77.12%
|
-2.55
|
| Sale Of PPE |
|
0.70
+973.85%
|
0.07
|
0.00
|
0.00
|
| Capital Expenditure |
|
—
|
-0.22
+62.09%
|
-0.58
+77.12%
|
-2.55
|
| Net Investment Purchase And Sale |
|
130.93
-25.91%
|
176.72
+502.77%
|
-43.88
+60.70%
|
-111.63
|
| Purchase Of Investment |
|
-139.49
-9.01%
|
-127.96
+76.70%
|
-549.18
-3.00%
|
-533.16
|
| Sale Of Investment |
|
270.41
-11.25%
|
304.68
-39.70%
|
505.31
+19.87%
|
421.53
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Gain Loss On Sale Of Business |
|
0.00
+100.00%
|
-0.08
|
0.00
|
0.00
|
| Financing Cash Flow |
|
-4.28
-4064.81%
|
0.11
-99.95%
|
237.30
-9.09%
|
261.04
|
| Cash Flow From Continuing Financing Activities |
|
-4.28
-4064.81%
|
0.11
-99.95%
|
237.30
-9.09%
|
261.04
|
| Net Common Stock Issuance |
|
-4.28
-1326.93%
|
0.35
-99.85%
|
237.30
-9.09%
|
261.04
|
| Common Stock Payments |
|
-9.98
|
0.00
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
-9.98
|
0.00
|
0.00
|
—
|
| Net Other Financing Charges |
|
—
|
-0.24
|
—
|
—
|
| Changes In Cash |
|
2.09
-63.95%
|
5.81
+138.79%
|
-14.98
+11.32%
|
-16.89
|
| Beginning Cash Position |
|
36.53
+18.91%
|
30.72
-32.78%
|
45.70
-26.98%
|
62.58
|
| End Cash Position |
|
38.62
+5.73%
|
36.53
+18.91%
|
30.72
-32.78%
|
45.70
|
| Free Cash Flow |
|
-125.25
+26.79%
|
-171.08
+17.91%
|
-208.41
-25.32%
|
-166.30
|
| Income Tax Paid Supplemental Data |
|
0.09
-76.32%
|
0.36
+156.43%
|
0.14
+1066.67%
|
0.01
|
| Amortization Of Securities |
|
-2.76
+65.47%
|
-8.00
+39.18%
|
-13.16
-253.21%
|
-3.73
|
| Common Stock Issuance |
|
5.69
+1531.52%
|
0.35
-99.85%
|
237.30
-9.09%
|
261.04
|
| Earnings Losses From Equity Investments |
|
0.00
|
0.00
-100.00%
|
16.01
-1.65%
|
16.28
|
| Issuance Of Capital Stock |
|
5.69
+1531.52%
|
0.35
-99.85%
|
237.30
-9.09%
|
261.04
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-17 View
- 8-K2026-04-09 View
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-04 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 8-K2026-01-09 View
- 42026-01-08 View
- 42025-12-15 View
- 8-K2025-12-15 View
- 10-Q2025-11-10 View
- 8-K2025-11-10 View
- 42025-10-01 View
- 8-K2025-08-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|